Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Biochem Pharmacol. 2013 Jul 15;86(2):191-9. doi: 10.1016/j.bcp.2013.04.022. Epub 2013 May 2.
Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that phosphorylates and inhibits glycogen synthase, thereby inhibiting glycogen synthesis from glucose. However, this serine/threonine kinase is now known to regulate numerous cellular processes through a number of signaling pathways important for cell proliferation, stem cell renewal, apoptosis and development. Because of these diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases, such as nervous system disorders, diabetes, bone formation, inflammation, cancer and heart failure. Therefore, GSK-3 is recognized as an attractive target for the development of new drugs. The present review summarizes the roles of GSK-3 in the insulin, Wnt/β-catenin and hedgehog signaling pathways including the regulation of their activities. The roles of GSK-3 in the development of human diseases within the context of its participation in various signaling pathways are also summarized. Finally, the possibility of new drug development targeting this kinase is discussed with recent information about inhibitors and activators of GSK-3.
糖原合酶激酶-3(GSK-3)是一种细胞质丝氨酸/苏氨酸蛋白激酶,可磷酸化并抑制糖原合酶,从而抑制葡萄糖向糖原的合成。然而,这种丝氨酸/苏氨酸激酶现在已知通过许多对细胞增殖、干细胞更新、细胞凋亡和发育很重要的信号通路来调节许多细胞过程。由于这些不同的作用,这种激酶的功能障碍也与人类疾病的发病机制有关,如神经系统疾病、糖尿病、骨形成、炎症、癌症和心力衰竭。因此,GSK-3 被认为是开发新药的有吸引力的靶标。本综述总结了 GSK-3 在胰岛素、Wnt/β-catenin 和 hedgehog 信号通路中的作用,包括对它们活性的调节。还总结了 GSK-3 在其参与各种信号通路的人类疾病发展中的作用。最后,根据 GSK-3 的抑制剂和激活剂的最新信息,讨论了针对这种激酶的新药开发的可能性。
Biochem Pharmacol. 2013-5-2
Trends Pharmacol Sci. 2004-9
IUBMB Life. 2015-12
Biochem Biophys Res Commun. 2001-11-23
Curr Opin Drug Discov Devel. 2008-7
Pharmaceuticals (Basel). 2025-3-28
Aging Biol. 2024-9-13
Transl Cancer Res. 2024-8-31
Front Cell Dev Biol. 2024-8-2
Heliyon. 2024-4-12